GLP-1 and Your Thyroid: What Every Hashimoto's Patient Needs to Know

In recent years, GLP-1 — glucagon-like peptide-1 — has moved out of endocrinology offices and into popular culture. Ozempic, Wegovy, Mounjaro: names every patient has heard of. But what few people know is that there is a direct, clinically relevant relationship between GLP-1 agonists and thyroid function — especially in patients with Hashimoto's or treated hypothyroidism.

What GLP-1 is and why it matters

GLP-1 is an incretin hormone produced by the L cells of the small intestine in response to eating. It stimulates insulin secretion in a glucose-dependent way, suppresses glucagon, slows gastric emptying, and acts on the central nervous system to promote satiety.

GLP-1 receptor agonists — semaglutide, liraglutide, and tirzepatide (which also acts on GIP) — mimic this effect over a longer period and are now used to treat type 2 diabetes and obesity. Their effectiveness for weight loss is undeniable. But the thyroid is very much part of the equation.

GLP-1 receptors in the thyroid

Animal studies have shown GLP-1 receptors on the parafollicular C cells of the thyroid — the same cells that produce calcitonin. In rodents, activation of these receptors was associated with C-cell hyperplasia and tumors, including medullary thyroid carcinoma. This finding led the FDA to issue a boxed warning (black box warning) for the entire drug class.

In humans, the data are more reassuring, but caution is mandatory. There is no solid evidence that GLP-1 agonists increase the risk of medullary carcinoma in patients without a genetic predisposition. Even so, their use is formally contraindicated in patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 (MEN 2).

GLP-1 and Hashimoto's: two opposite mechanisms you need to know about

For patients with Hashimoto's thyroiditis taking levothyroxine, GLP-1 agonists can push TSH in two opposite directions — and understanding the difference between them is essential for proper management.

What to expect with weight loss: TSH falls and the dose needs to come down

The expected pattern with weight loss is a drop in TSH. As fat mass decreases, systemic inflammation improves, metabolic demands go down, and the need for hormone replacement tends to fall. Patients with obesity are often on levothyroxine doses calibrated for a higher body weight — when they lose weight, that same dose becomes proportionally too high, suppressing TSH and requiring a reduction.

L-T4 dosing is weight-dependent: the reference is 1.6 to 1.8 mcg/kg/day based on ideal or lean body weight. With progressive weight loss on a GLP-1, adjusting the dose downward is the expected and necessary step — and bariatric surgery studies confirm this pattern, with a significant dose reduction as early as six months after weight loss.

The exception: impaired absorption can raise TSH

Delayed gastric emptying, a hallmark effect of GLP-1 agonists, can compromise levothyroxine absorption when it is taken with food or close to meals. With food staying longer in the gastrointestinal tract, the absorption window for L-T4 is disrupted — and in this specific scenario TSH may rise, signaling hypothyroidism due to malabsorption, not a truly insufficient dose.

That's why the fasting gap between L-T4 and the first meal — recommended at 30 to 60 minutes — must be strictly respected in these patients. Checking TSH and free T4 periodically is what makes it possible to tell the two mechanisms apart and respond correctly.

Calcitonin: should it be monitored?

Given the concern about C cells, some specialists recommend measuring baseline calcitonin before starting GLP-1 agonist therapy, especially in patients with thyroid nodules or a relevant family history. There is no universal consensus, but within an evidence-based Functional Integrative Health approach, this assessment is prudent and defensible.

What to monitor in patients on GLP-1

In clinical practice, I recommend the following thyroid follow-up for patients using GLP-1 agonists: TSH and free T4 every 3 months during the first 12 months of treatment, especially if weight loss is substantial; a review of the levothyroxine dose — usually downward — whenever weight drops by more than 5 to 10% from baseline; a thyroid ultrasound if there are known nodules or abnormal calcitonin; and extra attention in patients with active Hashimoto's, elevated anti-TPO antibodies, and borderline TSH.

Tirzepatide: a special note

Tirzepatide — a dual GLP-1 and GIP agonist — has outperformed semaglutide for weight loss in head-to-head comparison. For the thyroid, the same considerations apply, with one detail: its effect on gastric emptying may be even more pronounced, calling for even closer attention to levothyroxine absorption.

Clinical bottom line

GLP-1 agonists are powerful therapeutic tools — and they're here to stay. Weight loss tends to reduce the need for levothyroxine and TSH tends to fall — but delayed gastric emptying can impair absorption and raise TSH through a completely different mechanism. Monitoring, telling the two apart, and adjusting is what separates good follow-up from an incomplete prescription.

At the Dr. André Azevedo Clinic, we integrate weight-loss management with complete functional thyroid monitoring — because treating weight without caring for hormonal balance is only doing half the job.